HRP20150260T1 - Uporaba biotina za lijeäśenje multiple skleroze - Google Patents
Uporaba biotina za lijeäśenje multiple skleroze Download PDFInfo
- Publication number
- HRP20150260T1 HRP20150260T1 HRP20150260TT HRP20150260T HRP20150260T1 HR P20150260 T1 HRP20150260 T1 HR P20150260T1 HR P20150260T T HRP20150260T T HR P20150260TT HR P20150260 T HRP20150260 T HR P20150260T HR P20150260 T1 HRP20150260 T1 HR P20150260T1
- Authority
- HR
- Croatia
- Prior art keywords
- biotin
- multiple sclerosis
- treatment
- indicated
- drug
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims 32
- 229960002685 biotin Drugs 0.000 title claims 16
- 235000020958 biotin Nutrition 0.000 title claims 16
- 239000011616 biotin Substances 0.000 title claims 16
- 201000006417 multiple sclerosis Diseases 0.000 title claims 9
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 229940124622 immune-modulator drug Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Biotin naznačen time da je za uporabu za liječenje multiple skleroze.
2. Biotin za uporabu za liječenje multiple skleroze prema zahtjevu 1, naznačen time da multipla skleroza je primarni ili sekundarni progresivni oblik multiple skleroze.
3. Biotin naznačen time da je za uporabu za liječenje neuroloških posljedica nakon napada multiple skleroze.
4. Biotin prema bilo kojem zahtjevu od 1 do 3, naznačen time da dnevna količina biotina koja se daje pacijentu iznosi između 50 i 700 mg.
5. Biotin prema bilo kojem zahtjevu od 1 do 4, naznačen time da količina biotina koja se daje pacijentu iznosi između 100 i 300 mg.
6. Biotin prema bilo kojem zahtjevu od 1 do 5, naznačen time da je u obliku prikladnom za oralno davanje.
7. Biotin prema bilo kojem zahtjevu od 1 do 6, naznačen time da je u obliku želatinskih kapsula, tableta (po potrebi obloženih filmom), pastila ili pilula.
8. Biotin prema bilo kojem zahtjevu od 1 do 7, naznačen time da je u obliku pripravka koji sadrži biotin i pomoćne tvari, bez ikakvog drugog djelatnog sastojka.
9. Biotin prema zahtjevu 8, naznačen time da su pomoćne tvari odabrane iz skupine koja sadrži talk, mikrokristalnu celulozu, laktozu i manozu.
10. Biotin prema bilo kojem zahtjevu od 1 do 5, naznačen time da je u obliku prikladnom za davanje injektiranjem.
11. Biotin prema bilo kojem zahtjevu od 1 do 10, naznačen time da je u obliku za polagano otpuštanje pripravka.
12. Kombinacija biotina i drugog lijeka protiv multiple skleroze, za istovremenu, odvojenu ili sekvencijalnu (širenje tijekom vremena) uporabu naznačena time da se koristi u liječenju multiple skleroze.
13. Kombinacija prema zahtjevu 12, naznačena time da navedeni drugi lijek protiv multiple skleroze je imunomodulacijski ili imunosupresijski lijek.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1257254A FR2993780B1 (fr) | 2012-07-26 | 2012-07-26 | Methode de traitement de la sclerose en plaque |
| US13/644,615 US8835487B2 (en) | 2012-07-26 | 2012-10-04 | Method of treating multiple sclerosis |
| PCT/EP2013/058936 WO2014016003A1 (en) | 2012-07-26 | 2013-04-29 | Use of biotin for the treatment of multiple sclerosis |
| EP13719836.2A EP2729143B1 (en) | 2012-07-26 | 2013-04-29 | Use of biotin for the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150260T1 true HRP20150260T1 (hr) | 2015-05-08 |
Family
ID=47294963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150260TT HRP20150260T1 (hr) | 2012-07-26 | 2015-03-09 | Uporaba biotina za lijeäśenje multiple skleroze |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8835487B2 (hr) |
| EP (2) | EP2857019B1 (hr) |
| JP (1) | JP6208235B2 (hr) |
| KR (1) | KR101967502B1 (hr) |
| CN (2) | CN109908140A (hr) |
| AU (1) | AU2013295370B2 (hr) |
| BR (1) | BR112015001562A2 (hr) |
| CA (1) | CA2879434C (hr) |
| CY (1) | CY1116304T1 (hr) |
| DK (2) | DK2729143T3 (hr) |
| EA (1) | EA030478B1 (hr) |
| ES (3) | ES2811074T3 (hr) |
| FR (1) | FR2993780B1 (hr) |
| HK (1) | HK1207583A1 (hr) |
| HR (1) | HRP20150260T1 (hr) |
| HU (1) | HUE024558T2 (hr) |
| IL (1) | IL236790A (hr) |
| LT (1) | LT2857019T (hr) |
| ME (1) | ME02060B (hr) |
| PL (1) | PL2729143T3 (hr) |
| PT (2) | PT2857019T (hr) |
| RS (1) | RS53893B1 (hr) |
| SI (2) | SI2729143T1 (hr) |
| SM (1) | SMT201500057B (hr) |
| WO (1) | WO2014016003A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) * | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| CA2910717C (en) | 2013-04-29 | 2021-01-26 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| EP3257881B1 (en) * | 2015-02-13 | 2020-09-02 | Unimatec Co., Ltd. | Fluorinated copolymer, and surface modifier containing same as active ingredient |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
| RU2638803C2 (ru) * | 2016-06-09 | 2017-12-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки биотина с замедленным высвобождением и способ их получения |
| WO2017086835A1 (ru) * | 2015-11-17 | 2017-05-26 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты) |
| RU2611415C1 (ru) * | 2015-11-17 | 2017-02-21 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты) |
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| AU2017318672B2 (en) | 2016-09-01 | 2022-03-10 | Nutrition 21, Llc | Magnesium biotinate compositions and methods of use |
| RU2639488C1 (ru) * | 2017-04-06 | 2017-12-21 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Фармацевтическая композиция, содержащая биотин, и способ ее получения |
| WO2020102203A1 (en) * | 2018-11-13 | 2020-05-22 | Jds Therapeutics, Llc | Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions |
| CN112076310A (zh) * | 2019-06-14 | 2020-12-15 | 苏州融析生物科技有限公司 | 一种治疗多发性硬化的药物组合物及其制备 |
| AU2020407071A1 (en) | 2019-12-16 | 2022-07-07 | Nutrition 21, Llc | Methods of production of arginine-silicate complexes |
| JP2023509283A (ja) | 2020-01-01 | 2023-03-08 | セラジェネックス リサーチ （インディア） ピーブイティー リミテッド | Ａｔｐ効率を向上するための相乗的栄養組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3609165A (en) | 1968-07-19 | 1971-09-28 | Research Corp | 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes |
| JPH0995448A (ja) | 1995-09-29 | 1997-04-08 | Calpis Food Ind Co Ltd:The | 血中ビオチン濃度の増加方法およびビオチン含有飲食品 |
| EP0891719A1 (en) * | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
| US5789401A (en) | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
| US6664039B1 (en) | 1998-10-14 | 2003-12-16 | California Institute Of Technology | Methods and compositions for modulating neurodegeneration |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| DE19903241A1 (de) | 1999-01-28 | 2000-08-03 | Merck Patent Gmbh | Galenische Formulierung |
| US20050256178A1 (en) | 2002-08-23 | 2005-11-17 | Eggersdorfer Manfred L | Novel nutraceutical compositions comprising boitin |
| ATE472321T1 (de) | 2002-09-30 | 2010-07-15 | Daiichi Seiyaku Co | Pantethin enthaltendes teilchenförmiges produkt |
| DE10341240A1 (de) * | 2003-09-08 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| EP1706146B1 (en) * | 2003-12-31 | 2013-08-21 | K-Pax Pharmaceuticals, Inc. | Nutrient compositions and use thereof for enhanced effectiveness of the immune system |
| IL162288A0 (en) * | 2004-06-01 | 2005-11-20 | Future Products Man S A | Compositions and methods for treating neurodegenerative disorders |
| BG66011B1 (bg) * | 2005-05-25 | 2010-10-29 | Райна Щонова | Състав от растителен произход |
| MX2012007365A (es) | 2009-12-23 | 2012-08-15 | Lupin Ltd | Composiciones farmaceuticas de liberacion lenta de iloperidona. |
| FR2958166B1 (fr) * | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
-
2012
- 2012-07-26 FR FR1257254A patent/FR2993780B1/fr not_active Expired - Fee Related
- 2012-10-04 US US13/644,615 patent/US8835487B2/en active Active
-
2013
- 2013-04-29 ES ES14194213T patent/ES2811074T3/es active Active
- 2013-04-29 PT PT141942136T patent/PT2857019T/pt unknown
- 2013-04-29 EP EP14194213.6A patent/EP2857019B1/en active Active
- 2013-04-29 LT LTEP14194213.6T patent/LT2857019T/lt unknown
- 2013-04-29 DK DK13719836.2T patent/DK2729143T3/en active
- 2013-04-29 HU HUE13719836A patent/HUE024558T2/hu unknown
- 2013-04-29 BR BR112015001562A patent/BR112015001562A2/pt not_active Application Discontinuation
- 2013-04-29 PL PL13719836T patent/PL2729143T3/pl unknown
- 2013-04-29 EA EA201590270A patent/EA030478B1/ru not_active IP Right Cessation
- 2013-04-29 CN CN201910026016.2A patent/CN109908140A/zh active Pending
- 2013-04-29 JP JP2015523453A patent/JP6208235B2/ja not_active Expired - Fee Related
- 2013-04-29 AU AU2013295370A patent/AU2013295370B2/en not_active Ceased
- 2013-04-29 ES ES13719836.2T patent/ES2532364T3/es active Active
- 2013-04-29 ME MEP-2015-32A patent/ME02060B/me unknown
- 2013-04-29 CA CA2879434A patent/CA2879434C/en not_active Expired - Fee Related
- 2013-04-29 SI SI201330023T patent/SI2729143T1/sl unknown
- 2013-04-29 WO PCT/EP2013/058936 patent/WO2014016003A1/en active Application Filing
- 2013-04-29 CN CN201380039687.3A patent/CN104602689A/zh active Pending
- 2013-04-29 EP EP13719836.2A patent/EP2729143B1/en active Active
- 2013-04-29 SI SI201331768T patent/SI2857019T1/sl unknown
- 2013-04-29 DK DK14194213.6T patent/DK2857019T3/da active
- 2013-04-29 PT PT13719836T patent/PT2729143E/pt unknown
- 2013-04-29 RS RS20150168A patent/RS53893B1/en unknown
- 2013-04-29 KR KR1020157004516A patent/KR101967502B1/ko active IP Right Grant
-
2014
- 2014-01-14 ES ES14700423.8T patent/ES2626079T3/es active Active
- 2014-08-13 US US14/458,625 patent/US9351961B2/en not_active Expired - Fee Related
-
2015
- 2015-01-19 IL IL236790A patent/IL236790A/en active IP Right Grant
- 2015-03-09 SM SM201500057T patent/SMT201500057B/xx unknown
- 2015-03-09 HR HRP20150260TT patent/HRP20150260T1/hr unknown
- 2015-03-11 CY CY20151100243T patent/CY1116304T1/el unknown
- 2015-08-27 HK HK15108330.5A patent/HK1207583A1/xx unknown
-
2016
- 2016-04-12 US US15/096,957 patent/US10201528B2/en not_active Expired - Fee Related
-
2018
- 2018-12-21 US US16/231,073 patent/US20190117625A1/en not_active Abandoned
- 2018-12-21 US US16/231,111 patent/US20190117626A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150260T1 (hr) | Uporaba biotina za lijeäśenje multiple skleroze | |
| JP2015522630A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| BRPI0513598A (pt) | formas de dosagem em comprimidos revestidos de liberação entérica | |
| NZ599031A (en) | A dosage form containing two or more active pharmaceutical ingredients in different physical forms | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| WO2007103557A3 (en) | Coating capsules with active pharmaceutical ingredients | |
| JP2015523407A5 (hr) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2013231087A5 (hr) | ||
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| AU2012284627A8 (en) | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2015508082A5 (hr) | ||
| HRP20240121T1 (hr) | Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine | |
| JP2018527305A5 (hr) | ||
| WO2015087258A8 (en) | Modified-release therapeutic systems for oral administration of menthol in the treatment of intestinal disorders | |
| JP2020522560A5 (hr) | ||
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| EP2275110A3 (en) | Cladribine regimen for treating Multiple Sclerosis | |
| TN2011000307A1 (en) | Galenic formulation of organic compounds |